Abbott LaboratoriesvsKeros Therapeutics

ABT and KROS stock compared: price, dividend, valuation and results, from SEC filings.

ABT

Abbott Laboratories

$104.48

Value $182B

-0.22%
ABT's page

KROS

Keros Therapeutics, Inc.

$12.00

Value $237M

+6.10%
KROS's page

Abbott Laboratories (ABT) has a market value of $182B and Keros Therapeutics (KROS) $237M. Over the last year, with dividends, ABT moved -17.7% and KROS -30.9%. Dividend yield: ABT 2.41%, KROS none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ABT$182B

    KROS$237M

    ABT is 767 times KROS

  • Revenue, 12 months

    ABT$48.2B

    KROS$41M

    ABT is 1,183 times KROS

  • Net income, 12 months

    ABT$4.7B

    KROS-$62M

  • Operating margin

    ABT13.8%

    KROS-179.8%

    193.5 points apart

  • ROIC

    ABT6.3%

    KROS-15.8%

    22.1 points apart

  • P/E

    ABT38.6

    KROS–

  • Dividend yield

    ABT2.4%

    KROS0.0%

    2.4 points apart

  • 5-year return

    ABT-10.3%

    KROS-80.2%

    69.9 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ABT-10.3%

KROS-80.2%

5010020222023202420252026
Returns by period
PeriodABTWith dividendsKROSWith dividends
1 year since November 17, 2025-17.7%Price -19.6%-30.9%Price -30.9%
3 years since November 17, 2023+11.8%+3.8% a yearPrice +5.0%-60.4%-26.5% a yearPrice -60.4%
5 years since November 17, 2021-10.3%-2.1% a yearPrice -18.8%-80.2%-27.7% a yearPrice -80.2%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ABTAbbott LaboratoriesKROSKeros Therapeutics

Valuation

ABTKROS
Valuation
Price$104.48$12.00
Market value$182B$237M
Enterprise value (EV)$208B–
P/E38.6–
P/E, 5-year median33.7–
P/B3.60.9
EV/EBIT31.4–
Free cash flow yield3.7%–

Results and growth

ABTKROS
Results and growth
Revenue, 12 months$48.2B$41M
Net income, 12 months$4.7B-$62M
Free cash flow, 12 months$6.8B-$48M
Earnings per share, 12 months$2.69-$2.34
Revenue growth, year on year5.7%6,775.0%
Revenue growth a year, past+5.1%over 5 years–
EPS growth a year, past+8.3%over 5 years–

Margins and returns on capital

ABTKROS
Margins and returns on capital
Gross margin56.9%–
Operating margin13.8%-179.8%
Net margin9.8%-151.4%
ROIC6.3%-15.8%
ROE9.1%-16.8%

Balance sheet

ABTKROS
Balance sheet
Cash$4.3B$259M
Total debt$31.2B$15M
Net debt / EBITDA3.3–
Interest cover6.7×–

Dividends and buybacks

ABTKROS
Dividends and buybacks
Dividend yield2.4%–
Dividend per share, 12 months$2.52–
Dividend growth a year, past+10.4%over 5 years–
Buyback yield0.5%158.5%
Shareholder yield2.9%158.5%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ABT or KROS

Didn't find what you were looking for?

Ask us
Which is bigger, Abbott Laboratories or Keros Therapeutics?

By market value, Abbott Laboratories ($182B) is about 767.3 times Keros Therapeutics ($237M), at today's prices.

How did ABT and KROS stock do over the last 5 years?

Since November 17, 2021, ABT's price moved -18.8% and KROS's -80.2%. With dividends: ABT -10.3% (-2.1% a year), KROS -80.2% (-27.7% a year). Past returns do not predict future ones.

Which pays the higher dividend, ABT or KROS?

The dividend yield at today's price is 2.41% for Abbott Laboratories and none for Keros Therapeutics. Over the last twelve months they paid $2.52 and – per share.

Which has the higher profit margins, Abbott Laboratories or Keros Therapeutics?

Over the last twelve months, the net margin was 9.8% for Abbott Laboratories and -151.4% for Keros Therapeutics, and the operating margin 13.8% and -179.8%. Revenue was $48.2B and $41M.

Which is the better investment, Abbott Laboratories or Keros Therapeutics?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.